Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Fella Health vs Mint Med

Two GLP-1 desks, one scoreboard. We put Fella Health and Mint Med head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 42 · Grade B−

Fella Health

Visit Fella Health Full brief →
vs
No. 52 · Grade C

Mint Med

Visit Mint Med Full brief →

FDA warning letter, June 2026 — issued to Glow Medispa, LLC dba Mint Med. See the FDA's warning letter database.

The verdict

Fella Health takes this head-to-head.

Fella Health scores 81 to 79 on our six-factor Brief Score — A men's-health-focused program with an honest published state list — but a steep $399 tirzepatide line and no accreditation badge.

That doesn't make Mint Med a bad call — it's best for readers who want flat $159 all-doses compounded glp-1 with no membership. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
80
78
Supply Reliability
82
79
Transparency
84
88
Access Breadth
78
74
Clinical Oversight
79
86
Track Record
80
65
Fella HealthBrief Score 81 · 79Mint Med

Price, coverage & the tracker

Fella HealthMint Med
Brief Score81/100 (B−)79/100 (C)
Semaglutide$165/mo$159/mo
Tirzepatide$399/mo$159/mo
Coverage20 states36 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Fella Health: $165 sema but $399 tirz — one of the higher tirz lines; ~20 states, no accreditation.

Mint Med: New to the tracker on 1 August 2026. The published line reads $159/mo at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.